Why I Can’t Stop Buying Microsoft Even As Fears Of An AI Bubble Resurface

Photo of Alex Sirois
By Alex Sirois Published

Quick Read

  • MSFT has fallen 20% year to date while its AI business hit $37B ARR growing 123% and Azure surged 40% last quarter.

  • Amazon, Alphabet, and Oracle all chase enterprise AI dollars, but none can match Microsoft's $627B contracted backlog or $217B in TTM gross profit.

  • Paid Copilot seats surpassed 20 million, up 250% YoY, and Azure remains capacity constrained through 2026, signaling demand still outpacing supply.

  • Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Microsoft didn't make the cut. Grab the names FREE today.

I bought Microsoft again this week, and I will buy it again next week. The stock keeps getting cheaper while the business it represents keeps getting bigger, and that math is the whole confession.

Microsoft (NASDAQ:MSFT | MSFT Price Prediction) is the one hyperscaler willing to show the work on AI monetization. On the Q3 FY26 call, Satya Nadella told investors “Our AI business surpassed $37 billion ARR, up 123%.” That is booked revenue running at that pace right now.

Shares closed at $384.36 on Thursday, down 20.17% year to date and 23.05% over the past twelve months. Meanwhile Q3 FY26 revenue landed at $82.89 billion, up 18.3% YoY, EPS came in at $4.27 for a fourth straight beat, and Azure grew 40%. The panic lives in the ticker. The fundamentals kept working.

Three Numbers That Keep Me Buying

First, the backlog. Commercial remaining performance obligations reached $627 billion, up 99% YoY. That is contracted future revenue, nearly doubled in twelve months. When enterprises sign nine-figure checks committing to years of Azure and Copilot consumption, that reads as enterprise AI adoption in the plumbing.

Second, the quality of the earnings underneath it. Operating margin last quarter was 46.3%, return on equity is 34%, debt to equity sits at 0.176, and interest coverage runs at 53.89x. Microsoft guided to roughly $190 billion in calendar 2026 capex and still generated $71.61 billion of free cash flow in FY25. This is a fortress paying for its own construction crew.

Third, the valuation. Trailing P/E is 23, forward P/E is 20, and the stock trades well below its 200-day moving average of $443.59. Getting a 46% operating margin business growing revenue at 18% for a mid-20s multiple is when I stop asking clever questions.

Why Not Amazon, Alphabet, or Oracle

Amazon (NASDAQ:AMZN), Alphabet (NASDAQ:GOOGL), and Oracle (NYSE:ORCL) all compete for the same enterprise AI dollar. My money keeps going to Microsoft because none of them can show me a $627 billion RPO alongside a $37 billion AI run rate growing 123% sitting on top of $217 billion of TTM gross profit. That software annuity is what pays the GPU bill while the competition still argues about theirs.

The Real Risk

The $190 billion capex commitment is the thing that could actually hurt me. If enterprise AI monetization slows before the workflows compress, the return on that spend gets ugly. CFO Amy Hood addressed it directly: “We remain confident in the return on these investments given higher demand signals and increasing product usage.”

What keeps my finger on the buy button is what is already on the books. Paid Copilot seats crossed 20 million, up 250% YoY, with Accenture alone at 740,000 seats. Hood said Azure will stay capacity constrained “at least through 2026.” Demand exceeding supply reads as a queue forming.

One post on r/stocks last month put it plainly: “Microsoft is now cheaper than the April 2025 Tariff crash, yet TTM EPS is up 30%. Huge bargain.” The Street agrees on direction if not urgency: 54 buy ratings against three holds and zero sells.

My cost basis keeps improving. My share count keeps growing. Every ninety days Microsoft hands me another receipt. I am buying more.

Contact [email protected] for any questions or corrections.

Photo of Alex Sirois
About the Author Alex Sirois →

Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.

Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.

At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

META Vol: 40,760,422
KMX Vol: 2,288,021
WY Vol: 6,523,553
SBAC Vol: 1,443,801
NVDA Vol: 148,249,982

Top Losing Stocks

MRNA Vol: 9,176,778
CTRA Vol: 73,319,495
CRWD Vol: 9,269,567
DDOG Vol: 5,135,556
EPAM Vol: 1,164,561